Thomas McCulloh, DO
Family Medicine · Ardmore, OKNPI 1407879661
Payments from drug & device makers
Across 242 payments — averaging $14.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$680
- AbbVie$549
- AstraZeneca$431
- Sanofi-aventis U.S. LLC$364
- Amgen$262
- Novo Nordisk$219
- plus $931 from 18 others
What the payments were for
- Food & beverage$3,436100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 64 | $680 |
| AbbVie(2 entities) | 36 | $549 |
| AstraZeneca | 26 | $431 |
| Sanofi-aventis U.S. LLC | 24 | $364 |
| Amgen | 18 | $262 |
| Novo Nordisk | 13 | $219 |
| Astellas Pharma US Inc | 6 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $87 |
| Merck | 6 | $85 |
| Bayer | 6 | $82 |
| Sunovion Pharmaceuticals Inc. | 9 | $73 |
| Johnson & Johnson | 2 | $64 |
| Lilly USA, LLC | 4 | $60 |
| Teva Pharmaceuticals USA, Inc. | 4 | $57 |
| Boehringer Ingelheim | 4 | $53 |
| Ironwood Pharmaceuticals, Inc | 3 | $45 |
| Biogen | 3 | $43 |
| Pfizer | 3 | $41 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
How this compares
$3,436 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 105 | $105,486 |
| FarxigaDapagliflozin Propanediol | 96 | $94,314 |
| EliquisApixaban | 108 | $90,681 |
| Invega SustennaPaliperidone Palmitate | 12 | $39,121 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $37,042 |
| XareltoRivaroxaban | 17 | $25,365 |
| JardianceEmpagliflozin | 17 | $24,802 |
| TrulicityDulaglutide | 23 | $22,110 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $21,864 |
| EntrestoSacubitril/Valsartan | 25 | $21,102 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $19,860 |
| Victoza 3-PakLiraglutide | 20 | $17,878 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $13,483 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $12,754 |
| MyrbetriqMirabegron | 17 | $10,687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $219 | $105,486105 claims |
| AstraZenecaFarxiga, Symbicort | $431 | $101,134124 claims |
| PfizerEliquis | $41 | $90,681108 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $64 | $64,48529 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $680 | $50,52588 claims |
| Boehringer IngelheimJardiance | $53 | $24,80217 claims |
| Lilly USA, LLCTrulicity | $60 | $22,11023 claims |
| AbbVieLinzess, Synthroid | $549 | $15,53788 claims |
| Astellas Pharma US IncMyrbetriq | $138 | $10,68717 claims |
| BayerKerendia | $82 | $8,21611 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $87 | $5,18011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Ardmore
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.